These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28806944)

  • 1. Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.
    Eriksson D; Karlsson L; Eklund O; Dieperink H; Honkanen E; Melin J; Selvig K; Lundberg J
    BMC Health Serv Res; 2017 Aug; 17(1):560. PubMed ID: 28806944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The societal economic burden of autosomal dominant polycystic kidney disease in the United States.
    Cloutier M; Manceur AM; Guerin A; Aigbogun MS; Oberdhan D; Gauthier-Loiselle M
    BMC Health Serv Res; 2020 Feb; 20(1):126. PubMed ID: 32070341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life across all stages of autosomal dominant polycystic kidney disease.
    Eriksson D; Karlsson L; Eklund O; Dieperink H; Honkanen E; Melin J; Selvig K; Lundberg J
    Nephrol Dial Transplant; 2017 Dec; 32(12):2106-2111. PubMed ID: 27662885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
    Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
    J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
    Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
    BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.
    Knight T; Schaefer C; Krasa H; Oberdhan D; Chapman A; Perrone RD
    Clinicoecon Outcomes Res; 2015; 7():123-32. PubMed ID: 25759590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of chronic kidney disease in Korea using national sample cohort.
    Kim SH; Jo MW; Go DS; Ryu DR; Park J
    J Nephrol; 2017 Dec; 30(6):787-793. PubMed ID: 28303461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
    Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
    BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease.
    Blanchette CM; Iorga ŞR; Altan A; Seare JG; Fan Y; Rossetti S; Gutierrez B
    J Health Econ Outcomes Res; 2014; 2(1):63-74. PubMed ID: 37664083
    [No Abstract]   [Full Text] [Related]  

  • 12. Mortality risk in patients with autosomal dominant polycystic kidney disease.
    Mladsi D; Zhou X; Mader G; Sanon M; Wang J; Barnett C; Willey C; Seliger S
    BMC Nephrol; 2024 Feb; 25(1):56. PubMed ID: 38365638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
    Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
    Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing key cost drivers associated with caring for chronic kidney disease patients.
    Damien P; Lanham HJ; Parthasarathy M; Shah NL
    BMC Health Serv Res; 2016 Dec; 16(1):690. PubMed ID: 28031020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related difference in health care use and costs of patients with chronic kidney disease and matched controls: analysis of Dutch health care claims data.
    van Oosten MJM; Logtenberg SJJ; Leegte MJH; Bilo HJG; Mohnen SM; Hakkaart-van Roijen L; Hemmelder MH; de Wit GA; Jager KJ; Stel VS
    Nephrol Dial Transplant; 2020 Dec; 35(12):2138-2146. PubMed ID: 31598728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autosomal dominant polycystic kidney disease in Colombia.
    Camargo JT; González CA; Herrera L; Yomayusa-González N; Ibañez M; Valbuena-García AM; Acuña-Merchán L
    BMC Nephrol; 2023 Jul; 24(1):211. PubMed ID: 37460967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States.
    McGill RL; Saunders MR; Hayward AL; Chapman AB
    Clin J Am Soc Nephrol; 2022 Jul; 17(7):976-985. PubMed ID: 35725555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease.
    Ramanathan G; Periyasamy S; Lakkakula BV
    Nephrology (Carlton); 2014 Sep; 19(9):537-41. PubMed ID: 24824375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
    Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
    Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.